MOKAN Wealth Management Inc. Decreases Stock Position in Merck & Co., Inc. $MRK

MOKAN Wealth Management Inc. trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK) by 9.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,155 shares of the company’s stock after selling 4,785 shares during the period. Merck & Co., Inc. makes up 2.2% of MOKAN Wealth Management Inc.’s portfolio, making the stock its 12th biggest position. MOKAN Wealth Management Inc.’s holdings in Merck & Co., Inc. were worth $4,858,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRK. DLD Asset Management LP boosted its position in Merck & Co., Inc. by 30.1% in the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock valued at $3,986,675,000 after buying an additional 11,000,000 shares during the last quarter. Legal & General Group Plc increased its position in shares of Merck & Co., Inc. by 5.9% during the third quarter. Legal & General Group Plc now owns 20,659,157 shares of the company’s stock worth $1,733,923,000 after acquiring an additional 1,156,112 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Merck & Co., Inc. by 16.6% in the third quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock worth $1,665,585,000 after acquiring an additional 2,821,766 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Merck & Co., Inc. by 20.7% in the third quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock worth $1,336,877,000 after acquiring an additional 2,735,459 shares in the last quarter. Finally, Nordea Investment Management AB boosted its holdings in Merck & Co., Inc. by 2.0% in the third quarter. Nordea Investment Management AB now owns 10,945,187 shares of the company’s stock valued at $876,600,000 after purchasing an additional 209,759 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on MRK shares. Barclays began coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They set an “overweight” rating and a $140.00 price objective for the company. TD Cowen increased their target price on Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a research note on Tuesday, January 20th. Royal Bank Of Canada reissued an “outperform” rating and set a $142.00 price target on shares of Merck & Co., Inc. in a research report on Monday, March 30th. BMO Capital Markets upgraded shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $82.00 to $130.00 in a research note on Thursday, December 18th. Finally, Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $128.47.

Insider Activity

In other Merck & Co., Inc. news, CFO Caroline Litchfield sold 41,997 shares of the stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total transaction of $5,023,261.17. Following the sale, the chief financial officer directly owned 90,192 shares of the company’s stock, valued at approximately $10,787,865.12. This represents a 31.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Chirfi Guindo sold 20,000 shares of the stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the sale, the chief marketing officer directly owned 80,615 shares in the company, valued at $9,825,356.20. This trade represents a 19.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 320,176 shares of company stock valued at $38,281,735 over the last three months. 0.09% of the stock is currently owned by company insiders.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA granted Priority Review to Merck and Daiichi Sankyo’s BLA for ifinatamab deruxtecan for previously treated extensive‑stage small cell lung cancer — if approved this could be a first‑in‑class B7‑H3 antibody‑drug conjugate with meaningful upside to oncology revenue. Article
• Positive Sentiment: UBS raised its price target on MRK from $130 to $145 and maintained a Buy rating, signaling analyst confidence in Merck’s growth trajectory and providing a potential catalyst for upside. Article
• Neutral Sentiment: Industry context — large pharma shifting to smaller, disciplined deals may leave room for strategic partnerships and targeted M&A that could benefit Merck or its competitors, but no direct near‑term impact is specified. Article
• Neutral Sentiment: Sector moves: positive clinical readouts at peers (e.g., Revolution Medicines) are lifting biotech sentiment broadly — this can shift investor flows within healthcare but does not directly change Merck’s fundamentals. Article
• Neutral Sentiment: Investor commentary pieces highlight profitability as an important factor for long‑term holders; Merck’s margins and guidance remain points investors watch but are not new catalysts. Article
• Negative Sentiment: Reputational and policy risk: reporting on how Merck built a broad patent “wall” around Keytruda and the high U.S. costs underscores political, regulatory and payer scrutiny that could pressure pricing and future revenue. Article
• Negative Sentiment: Near‑term selling pressure noted in recent market reports — short‑term stock weakness has appeared even as company news flows positive, suggesting traders are balancing the FDA news with broader market and sector dynamics. Article

Merck & Co., Inc. Stock Down 0.2%

NYSE:MRK opened at $119.94 on Wednesday. The company has a market capitalization of $296.24 billion, a price-to-earnings ratio of 16.48, a price-to-earnings-growth ratio of 2.42 and a beta of 0.26. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $125.14. The stock has a 50-day simple moving average of $119.27 and a 200 day simple moving average of $105.42. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm had revenue of $16.40 billion for the quarter, compared to analysts’ expectations of $16.19 billion. During the same quarter in the prior year, the firm posted $1.72 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Sell-side analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 16th were given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend was Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.